Mendelian randomization does not support serum calcium in prostate cancer risk.
Purpose: Observational studies suggest that dietary and serum calcium are risk factors for prostate cancer. However, such studies suffer from residual confounding (due to unmeasured or imprecisely measured confounders), undermining causal inference. Mendelian randomization uses randomly assigned (he...
| Publicado en: | Cancer Causes & Control Vol. 29; no. 11; pp. 1073 - 1081 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Nov2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132945707&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 132945707 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09575243 ODX jtl: Cancer Causes & Control issn: 09575243 maglogo: N pubinfo: dt: Nov2018 vid: 29 iid: 11 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 132945707 132945707 NLM30306355 10.1007/s10552-018-1081-5 NLM30306355 132945707 ppf: 1073 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Mendelian randomization does not support serum calcium in prostate cancer risk. aug: au: Yarmolinsky, James Berryman, Katie Langdon, Ryan Bonilla, Carolina PRACTICAL consortium Davey Smith, George Martin, Richard M. Lewis, Sarah J. affil: MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK sug: subj: Prostatic Neoplasms Epidemiology Calcium, Dietary Blood Calcium Blood Prostatic Neoplasms Blood Polymorphism, Genetic Prostatic Neoplasms Genetics Male Phenotype Sequence Analysis Odds Ratio Prostatic Neoplasms Etiology Calcium, Dietary Adverse Effects Risk Factors Male ab: Purpose: Observational studies suggest that dietary and serum calcium are risk factors for prostate cancer. However, such studies suffer from residual confounding (due to unmeasured or imprecisely measured confounders), undermining causal inference. Mendelian randomization uses randomly assigned (hence unconfounded and pre-disease onset) germline genetic variation to proxy for phenotypes and strengthen causal inference in observational studies. We tested the hypothesis that serum calcium is associated with an increased risk of overall and advanced prostate cancer.Methods: A genetic instrument was constructed using five single-nucleotide polymorphisms robustly associated with serum calcium in a genome-wide association study (n ≤ 61,079). This instrument was then used to test the effect of a 0.5 mg/dL increase (1 standard deviation, SD) in serum calcium on risk of prostate cancer in 72,729 men in the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) Consortium (44,825 cases, 27,904 controls) and risk of advanced prostate cancer in 33,498 men (6,263 cases, 27,235 controls).Results: We found weak evidence for a protective effect of serum calcium on prostate cancer risk (odds ratio [OR] per 0.5 mg/dL increase in calcium: 0.83, 95% CI 0.63-1.08; p = 0.12). We did not find strong evidence for an effect of serum calcium on advanced prostate cancer (OR per 0.5 mg/dL increase in calcium: 0.98, 95% CI 0.57-1.70; p = 0.93).Conclusions: Our Mendelian randomization analysis does not support the hypothesis that serum calcium increases risk of overall or advanced prostate cancer. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|